Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Magnesium dithiosalicylate is a **salicylate derivative** that was evaluated as an anti-inflammatory agent. In a controlled clinical trial, 3 g daily showed anti-inflammatory effectiveness comparable to aspirin (3 g) in the treatment of rheumatoid arthritis, with significant reductions in morning stiffness, tender joints, pain score, and erythrocyte sedimentation rate. However, magnesium dithiosalicylate was associated with a high frequency of side effects, particularly hypersensitivity reactions, making it clinically unacceptable for the treatment of rheumatoid arthritis. Its mechanism of action is presumed similar to that of other salicylates, likely involving **nonselective inhibition of cyclooxygenase (COX-1 and COX-2)**, thereby reducing prostaglandin synthesis and inflammation[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnesium dithiosalicylate.